

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

SERIAL NO.

2370-11

08/260,536

APPLICANT

Robert M. LORENCE et al

(Use several sheets if necessary)

FILING DATE

TC/A.U.

June 16, 1994

1648

U.S. PATENT DOCUMENTS

| *EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|----------------------|-----------------|------|------|-------|----------|-------------------------------|
| | | | | | | |

FOREIGN PATENT DOCUMENTS

| DOCUMENT | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION YES NO |
|----------|------|---------|-------|----------|-----------------------|
| | | | | | |

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

| | |
|----|--|
| de | Clercq, E.D., et al; "Current Concepts of Interferon and Interferon Induction"; <i>Division of Infectious Diseases, Dept. of Medicine, Stanford University School of Medicine, Stanford, California</i> ; pp. 17-46 (1970). |
| | Hilleman, M.R.; "Interferon Induction and Utilization"; <i>J. Cell Physiol.</i> ; Vol. 71 pp. 43-60 (1968). |
| | Eaton, M.D., et al; "Contribution of Antiviral Immunity to Oncolysis by Newcastle Disease Virus in a Murine Lymphoma"; <i>Journal of the National Cancer Institute</i> ; Vol. 39, No. 1-6 pp. 1089-1097 (1967). |
| | Dalgleish, A.G., et al; "The Development of Therapeutic Vaccines for the Management of Malignant Melanoma"; <i>Cancer Surveys</i> , Vol. 26; pp. 289-319 (1996). |
| | Japanese Patent Office; Public Patent Disclosure Bulletin No. S51-73117; Bulletin Date June 24, 1976; Patent Application No. S49-147261; Patent Application Date; December 19, 1974, (6 pgs). |
| | Nature New Biology; Vol. 245, No. 147, October 24, 1973, "Role of Interferon in the Anti-Melanoma Effects of Poly (I), Poly (C) and Newcastle Disease Virus; pp 229-230. |
| | Baars, A., et al; "Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: Experience in 81 patients"; <i>Annals of Oncology</i> ; Vol. 11, pp. 965-970 (2000). |
| | Schirmacher, V.; "In situ analysis of tumor-specific CTL effector and memory responses elicited by tumor vaccination"; <i>International Journal of Oncology</i> ; Vol. 15; pp. 27-227 (1999). |
| | Vile, R.G.; "Virology-not yet, but soon?"; <i>Nature Biotechnology</i> , Nature Publishing Group; Vol. 19 pp. 1020-1022, (2001). |
| | Yotnda, P., et al; "Targeted delivery of adenoviral vectors by cytotoxic T cells"; <i>Blood</i> ; Vol. 104, No. 8, pp 2272-2280 (2004). |
| | Harrington, K., et al; "Cells as Vehicles for Cancer Gene Therapy: The Missing Link Between Targeted Vectors and Systemic Delivery"; <i>Human Gene Therapy</i> ; Vol. 13; pp. 1263-1280 (2002). |
| | Crystal, R.G., et al; "Analysis of Risk Factors for Local Delivery of Low- and Intermediate-Dose Adenovirus Gene Transfer Vectors to Individuals with a Spectrum of Comorbid Conditions"; <i>Human Gene Therapy</i> ; Vol. 13; pp. 65-100 (2002). |
| | Chen, Y., et al; "Pre-Existent Adenovirus Antibody Inhibits Systemic Toxicity and Antitumor Activity of CN706 in the Nude Mouse LNCaP Xenograft Model: Implications and Proposals for Human Therapy"; <i>Human Gene Therapy</i> ; Vol. 11; pp. 1553-1567 (2000). |
| | Jia, W., et al; "Viral Vectors for Cancer Gene Therapy: Viral Dissemination and Tumor Targeting"; <i>Current Gene Therapy</i> ; Vol. 5, pp. 133-142 (2005). |
| | Morrissey, R.E., et al; "Rodent Nonclinical Safety Evaluation Studies of SCH 58500, an Adenoviral Vector for the p53 Gene"; <i>Toxicological Sciences</i> ; Vol. 65, pp. 266-275 (2002). |
| | Plager, C., et al; "Adjuvant Immunotherapy of M.D. Anderson Hospital (MDAH Stage III-B Malignant Melanoma with Newcastle Disease Virus Oncolysate"; <i>Proceedings of American Society of Clinical Oncology</i> ; Vol. 9 p 281; #1091 (March 1990) |
| U | Leibrich, W., et al; "In vitro and Clinical Characterisation of a Newcastle Disease Virus-modified Autologous Tumour Cell Vaccine for Treatment of Colorectal Cancer Patients"; <i>Eur J. Cancer</i> ; Vol. 27, No. 6, pp (703-710 (1991). |

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

INFORMATION DISCLOSURE
CITATION

ATTY. DOCKET NO.

SERIAL NO.

2370-11

08/260,536

APPLICANT

Robert M. LORENCE et al

(Use several sheets if necessary)

FILING DATE

TC/A.U.

June 16, 1994

1648

| | |
|-----|---|
| ele | Mallmann, P.; "Autologous Tumor-Cell Vaccination and Lymphokine-Activated Tumor-Infiltrating Lymphocytes (LAK-TIL); <i>Hybridoma</i> ; Vol. 12, No. 5, pp 559-566 (1993). |
| ele | Murray, D.R., et al; "Viral Oncolysate in the Management of Malignant Melanoma II. Clinical Studies"; <i>Cancer</i> ; Vol. 46, No. 2; pp680-686 (1977). |

*Examiner

Emily Le

Date Considered

1/06/06

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

| | | |
|--|---------------------------------------|---------------|
| Form PTO-1449 U.S. DEPT. OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) | ATTY. DKT. NO. | SERIAL NO. |
| | PROVI 2 | 08/260,536 |
| | APPLICANT Robert M. LORENCE et al. | |
| | FILING DATE June 16, 1994 | GROUP 1813 |

U.S. PATENT DOCUMENTS

| Examiner Initial | Document Number | Date | Name | Class | Subclass | Filing Date |
|------------------|-----------------|------|------|-------|----------|-------------|
| | AA | | | | | |
| | AB | | | | | |
| | AC | | | | | |
| | AD | | | | | |
| | AE | | | | | |
| | AF | | | | | |
| | AG | | | | | |
| | AH | | | | | |
| | AI | | | | | |
| | AJ | | | | | |
| | AK | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initial | Document Number | Date | Country | Class | Subclass | Translation | |
|------------------|-----------------|----------|---------|-------|----------|-------------|----|
| | | | | | | Yes | No |
| <i>elo</i> | AL 58-116422 | 07/11/58 | JP | | | x | |
| | AM | | | | | | |
| | AN | | | | | | |
| | AO | | | | | | |
| | AP | | | | | | |
| | AQ | | | | | | |
| | AR | | | | | | |
| | AS | | | | | | |
| | AT | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|----------------------------|----|--|
| <i>elo</i> | AU | Ahlert et al., "Isolation of a Human Melanoma Adapted Newcastle," <u>Cancer Res.</u> , 50:5962-5968, 1990. |
| | AW | |
| | AX | |
| | | |
| Examiner <i>Carly L</i> | | Date Considered <i>1/06/06</i> |

**INFORMATION DISCLOSURE
CITATION**

ATTY. DOCKET NO.

SERIAL NO.

2370-11

08/260,536

APPLICANT

Robert M. LORENCE et al

FILING DATE

GROUP

June 16, 1994

1648



several sheets if necessary)

RECEIVED
JUL 29 2003
TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

OTHER DOCUMENTS (including Author, Title, Date, Pertinent pages, etc.)

[illegible]

*Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.